Genelux (GNLX) Prepaid Assets (2022 - 2026)

Genelux (GNLX) posted quarterly Prepaid Assets of $545000.0 for Q1 2026, up 1.87% quarter-over-quarter from $535000.0 in Q4 2025.

Genelux (GNLX) Prepaid Assets (2022 - 2026) Analysis & Trends

Genelux's Prepaid Assets history runs 5 years deep, the most recent figure standing at $545000.0 for Q1 2026.

In Q1 2026, Prepaid Assets changed N/A year-over-year to $545000.0; the TTM figure through Mar 2026 stood at $545000.0 (changed N/A YoY), while the FY2025 annual figure was $535000.0, down 18.07% from the prior year.
Prepaid Assets for Q1 2026 stood at $545000.0, up from $535000.0 in the prior quarter.
The five-year high for Prepaid Assets was $1.9 million in Q3 2024, with the low at $535000.0 in Q4 2025.
The 5-year median for Prepaid Assets is $1.2 million (2024), against an average of $1.1 million.
The sharpest annual moves came in 2024 and 2025: Prepaid Assets jumped 45.8% in 2024, then plunged 66.65% in 2025.
Genelux's Prepaid Assets stood at $1.5 million in 2022, then plunged by 32.31% to $1.0 million in 2023, then plunged by 35.47% to $653000.0 in 2024, then declined by 18.07% to $535000.0 in 2025, then climbed by 1.87% to $545000.0 in 2026.
Business Quant data shows GNLX's Prepaid Assets at $545000.0 in Q1 2026, $535000.0 in Q4 2025, and $637000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Genelux	119.87 Mn	119.87 Mn	-

Download Data